ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Saliva, urine, and anorectal swabs as viable alternatives to lesion swabs for molecular diagnosis of mpox.Nature communications · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite 2 public health emergency declarations, limited progress has been made in the development of essential medical countermeasures for mpox, including therapeutics and point-of-care (POC) diagnostics. We analyzed mpox diagnostics registered in a public database in December 2022 and January 2025. The number of tests increased; however, independent validation lagged behind. While the World Health Organization has granted emergency use listing to 2 POC molecular tests, there are no independently validated antigen rapid diagnostic tests (AgRDTs) essential for decentralized detection. The therapeutics pipeline has shown minimal progress since 2022. Of 17 clinical trials, 14 evaluated direct-acting antivirals; 86% focused solely on tecovirimat, a drug that shows safety but not efficacy with documented resistance concerns. Key vulnerable populations, including children, pregnant women, and people with human immunodeficiency virus, remain absent from studies despite higher mortality rates. Our pipeline analysis revealed a fundamental mismatch between available countermeasures and actual needs, particularly in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.